Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
85.72(c) 84.62(c) 83.36(c) 82.74(c) 82.94(c) Last
997 632 1 473 313 1 868 864 1 888 397 1 224 867 Volume
-0.36% -1.28% -1.49% -0.74% +0.24% Change
More quotes
Financials
Sales 2020 36 584 M 43 393 M 43 393 M
Net income 2020 11 429 M 13 556 M 13 556 M
Net Debt 2020 7 902 M 9 373 M 9 373 M
P/E ratio 2020 9,17x
Yield 2020 3,85%
Sales 2021 38 170 M 45 273 M 45 273 M
Net income 2021 5 754 M 6 824 M 6 824 M
Net Debt 2021 5 110 M 6 061 M 6 061 M
P/E ratio 2021 17,6x
Yield 2021 4,04%
Capitalization 104 B 123 B 124 B
EV / Sales 2020 3,06x
EV / Sales 2021 2,86x
Nbr of Employees 100 409
Free-Float 89,0%
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (84.1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies, etc. Moreover, Sanofi-Aventis markets OTC products and generic drugs; - human vaccines (15.9%): pediatric vaccines,... 
More about the company
Notations Surperformance© of Sanofi
Trading Rating : Investor Rating :
More Ratings
All news about SANOFI
10/24To Find a Coronavirus Vaccine, GlaxoSmithKline Is -2-
DJ
10/24To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
DJ
10/23Canada to invest up to C$214 mln for research into domestic-made vaccines - P..
RE
10/22SANOFI : Flublok vaccine given authorisation for temporary supply in the UK to m..
AQ
10/22European cities plead for more flu shots as winter looms, pandemic rages
RE
10/22S.Korea sticks to flu vaccine plan despite safety fears after 25 die
RE
10/21Number of South Koreans dying after flu shot rises, prompts vaccine worries
RE
10/21SANOFI : Merck and Sanofi to Present Three New Studies Highlighting Combination ..
AQ
10/21SANOFI : and the Parkinson's Foundation collaborate to advance the availability ..
PR
10/21SANOFI : EU signs supply deal with J&J on potential COVID-19 vaccine
RE
10/21ENZYMATICA : enters agreement with Sanofi for covering France and Italy on commo..
AQ
10/21GSK to launch late-stage testing of syncytial virus vaccine
RE
10/20SANOFI : Must A "Human Antibody" Be Entirely Human? Or May It Also Be "Partially..
AQ
10/19France's Ose to enrol up to 400 for 'T-cell' coronavirus vaccine trials
RE
10/19France's Ose to enroll up to 400 for 'T-cell' coronavirus vaccine trials
RE
More news
News in other languages on SANOFI
10/23COVID-19 : le Canada annonce un accord pour un vaccin canadien
10/23MINISTERIUM BEKRÄFTIGT : Corona-Impfungen voraussichtlich Anfang 2021
10/23BB Biotech sombre dans le rouge au 3e trimestre, reste à flot sur 9 mois
10/19SANOFI : Goldman Sachs à l'achat
10/19Goldman hebt Ziel für Sanofi auf 110 Euro - 'Buy'
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 09/04
One could take advantage of the market's hesitation
BUY
More Stock Trading Analysis
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 105,53 €
Last Close Price 82,94 €
Spread / Highest target 48,1%
Spread / Average Target 27,2%
Spread / Lowest Target 2,48%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-7.45%123 347
JOHNSON & JOHNSON-0.43%382 350
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999